Polymyxins revisited

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• The rise of multidrug-resistant gram-negative bacilli has led to a resurgence in the use of polymyxins, antibiotics previously limited by toxicity concerns.
• Polymyxins are now essential for treating infections caused by resistant pathogens like Pseudomonas aeruginosa and Acinetobacter baumannii.
• Despite their renewed importance, optimal dosing strategies and reliable in vitro susceptibility testing methods for polymyxins require further investigation.

Purpose of the Study:

• To review the current role and challenges associated with polymyxin use in clinical practice.
• To highlight the need for standardized in vitro testing and established breakpoints for polymyxins.
• To discuss the clinical efficacy and safety of polymyxins in comparison to other antibiotic classes.

Main Methods:

• Review of contemporary clinical studies and surveillance data on polymyxin usage.
• Analysis of in vitro susceptibility testing methodologies and their reliability.
• Evaluation of clinical outcomes and toxicity profiles in patients treated with polymyxins.

Main Results:

• Polymyxin therapy for multidrug-resistant infections shows comparable clinical response and toxicity rates to carbapenem therapy for susceptible infections.
• While most studies report high susceptibility rates, the emergence of polymyxin-resistant strains is a growing concern.
• Polymyxins have established a significant role in managing hospital-acquired infections.

Conclusions:

• Polymyxins are indispensable agents for treating infections caused by multidrug-resistant gram-negative bacteria.
• Further research into optimal dosing and standardized in vitro diagnostics is critical for maximizing polymyxin efficacy and safety.
• Continued investigation into polymyxin use will ensure their sustained clinical utility against evolving resistant pathogens.